Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure
CONTRACT
1 other identifier
interventional
52
1 country
1
Brief Summary
To compare a surgical approach of LV lead placement for BIV pacing with the conventional transvenous approach by assessment of differences on the effects on cardiac perfusion and relate this to the clinical cardiac function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 30, 2007
CompletedFirst Posted
Study publicly available on registry
October 31, 2007
CompletedStudy Start
First participant enrolled
November 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedApril 21, 2016
April 1, 2016
7.3 years
October 30, 2007
April 20, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Degree of change in cardiac perfusion following epicardial LV lead placement, compared to transvenous LV lead placement
6 months
Secondary Outcomes (1)
Resynchronization of the LV, measured with TDI, 2D- and 3D-echocardiography, in patients with epicardial LV lead placement, compared to transvenous LV lead placement
6 months
Study Arms (2)
1
ACTIVE COMPARATOREpicardial left ventricular lead placement
2
ACTIVE COMPARATORtransvenous left ventricular lead
Interventions
epicardial left ventricular lead placement
implantation of biventricular pacemaker with transvenous left ventricular lead placement
Eligibility Criteria
You may qualify if:
- Heart failure NYHA III or IV
- QRS duration \>120msec or, when paced \> 200msec on 12-lead ECG
- LBBB on ecg
- LV ejection fraction 35% or less
- LV dyssynchony on echocardiography
You may not qualify if:
- Severe (drug refractory) heart failure with short (\<6 months) life expectancy.
- Permanent or persistent atrial fibrillation
- Other indications for cardiac surgery within 6 months
- Life expectancy less than one year due to other conditions
- Major contra-indication for general anaesthesia
- Participation in another study
- Pregnancy or the desire to become pregnant during the follow up of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- R&D Cardiologielead
Study Sites (1)
St Antonius Hospital
Nieuwegein, Utrecht, 3435 CM, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lucas VA Boersma, MD, PHD
St. Antonius Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
October 30, 2007
First Posted
October 31, 2007
Study Start
November 1, 2007
Primary Completion
February 1, 2015
Study Completion
August 1, 2015
Last Updated
April 21, 2016
Record last verified: 2016-04